​

Roivant Sciences (ROIV) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

ROIV Stock Forecast

Roivant Sciences (ROIV) stock forecast, based on 13 Wall Street analysts, predicts a 12-month average price target of $16.21, with a high of $20.00 and a low of $12.50. This represents a 41.94% increase from the last price of $11.42.

$10 $12 $14 $16 $18 $20 High: $20 Avg: $16.21 Low: $12.5 Last Closed Price: $11.42

ROIV Stock Rating

Roivant Sciences stock's rating consensus is Buy, based on 13 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 12 Buy (92.31%), 1 Hold (7.69%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 13 1 12 0 Strong Sell Sell Hold Buy Strong Buy

ROIV Price Target Upside V Benchmarks

TypeNameUpside
StockRoivant Sciences41.94%
SectorHealthcare Stocks 19.91%
IndustryBiotech Stocks 55.52%

Price Target Trends

1M3M12M
# Anlaysts--3
Avg Price Target--$15.50
Last Closing Price$11.42$11.42$11.42
Upside/Downside--35.73%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jul, 25351--9
Jun, 25361--10
May, 25361--10
Apr, 25361--10
Mar, 25351--9
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 21, 2024David RisingerLeerink Partners$17.00$11.9242.62%48.86%
Sep 19, 2024Corinne JenkinsGoldman Sachs$17.00$12.0640.96%48.86%
Sep 11, 2024Chi FongBank of America Securities$12.50$12.460.32%9.46%
May 31, 2024Allison BratzelPiper Sandler$20.00$10.3992.49%75.13%
Apr 03, 2024Douglas TsaoH.C. Wainwright$18.00$10.9264.84%57.62%
Apr 03, 2024Neena Bitritto-GargDeutsche Bank$15.00$10.9237.36%31.35%
Apr 02, 2024Corinne JenkinsGoldman Sachs$18.00$10.9264.84%57.62%
Mar 13, 2024Corinne JenkinsGoldman Sachs$16.00$10.6250.66%40.11%
Jan 05, 2023Citigroup$14.00$7.5685.19%22.59%
Dec 19, 2022Leerink Partners$10.00$7.3236.61%-12.43%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jun 18, 2025CitigroupOverweightOverweighthold
Oct 21, 2024Leerink PartnersOutperformOutperformhold
Sep 19, 2024Goldman SachsBuyBuyhold
Sep 11, 2024H.C. WainwrightUnderperformUnderperformhold
Sep 11, 2024Cowen & Co.BuyBuyhold
Sep 11, 2024H.C. WainwrightBuyBuyhold
Sep 11, 2024Bank of America SecuritiesNeutralNeutralhold
Jul 10, 2024Piper SandlerOverweightOverweighthold
May 31, 2024Goldman SachsUnderperformUnderperformhold
May 31, 2024Piper SandlerOverweightOverweighthold

Financial Forecast

EPS Forecast

$-3 $-2 $-1 $0 $1 $2 $3 $4 $5 $6 Mar 23 Mar 24 Mar 24 Mar 25 Mar 26 Mar 27 Mar 28 Mar 29
Mar 23Mar 24Mar 25Mar 26Mar 27Mar 28Mar 29
Reported$-1.42$5.55-----
Avg Forecast$-1.59$5.22$-0.77$-1.09$-1.07$-0.47$0.20
High Forecast$-0.73$5.41$-0.72$-0.81$-0.82$-0.22$0.33
Low Forecast$-2.63$4.98$-0.81$-1.29$-1.39$-0.77$0.09
Surprise %-10.69%6.32%-----

Revenue Forecast

$0 $500M $1B $2B $2B $3B Mar 23 Mar 24 Mar 24 Mar 25 Mar 26 Mar 27 Mar 28 Mar 29
Mar 23Mar 24Mar 25Mar 26Mar 27Mar 28Mar 29
Reported$61.28M$124.80M-----
Avg Forecast$52.28M$181.74M$92.10M$34.74M$61.48M$762.32M$1.57B
High Forecast$78.79M$193.36M$139.48M$59.09M$92.67M$1.15B$2.37B
Low Forecast$30.60M$176.37M$56.33M$17.27M$35.98M$446.16M$920.09M
Surprise %17.22%-31.33%-----

Net Income Forecast

$-3B $-1B $300M $2B $3B $5B Mar 23 Mar 24 Mar 24 Mar 25 Mar 26 Mar 27 Mar 28 Mar 29
Mar 23Mar 24Mar 25Mar 26Mar 27Mar 28Mar 29
Reported$-1.01B$4.35B-----
Avg Forecast$-1.32B$4.35B$-605.08M$-804.05M$-911.26M$-387.83M$163.44M
High Forecast$-608.11M$4.50B$-596.22M$-672.44M$-682.96M$-178.73M$271.22M
Low Forecast$-2.19B$4.14B$-670.75M$-1.07B$-1.15B$-643.57M$75.32M
Surprise %-23.53%-0.07%-----

ROIV Forecast FAQ

Is Roivant Sciences stock a buy?

Roivant Sciences stock has a consensus rating of Buy, based on 13 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 12 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Roivant Sciences is a favorable investment for most analysts.

What is Roivant Sciences's price target?

Roivant Sciences's price target, set by 13 Wall Street analysts, averages $16.21 over the next 12 months. The price target range spans from $12.5 at the low end to $20 at the high end, suggesting a potential 41.94% change from the previous closing price of $11.42.

How does Roivant Sciences stock forecast compare to its benchmarks?

Roivant Sciences's stock forecast shows a 41.94% upside, outperforming the average forecast for the healthcare stocks sector (19.91%) and underperforming the biotech stocks industry (55.52%).

What is the breakdown of analyst ratings for Roivant Sciences over the past three months?

  • July 2025: 33.33% Strong Buy, 55.56% Buy, 11.11% Hold, 0% Sell, 0% Strong Sell.
  • June 2025: 30.00% Strong Buy, 60.00% Buy, 10.00% Hold, 0% Sell, 0% Strong Sell.
  • May 2025: 30.00% Strong Buy, 60.00% Buy, 10.00% Hold, 0% Sell, 0% Strong Sell.

What is Roivant Sciences’s EPS forecast?

Roivant Sciences's average annual EPS forecast for its fiscal year ending in March 2025 is $-0.77, marking a -113.87% decrease from the reported $5.55 in 2024. Estimates for the following years are $-1.09 in 2026, $-1.07 in 2027, $-0.47 in 2028, and $0.2 in 2029.

What is Roivant Sciences’s revenue forecast?

Roivant Sciences's average annual revenue forecast for its fiscal year ending in March 2025 is $92.1M, reflecting a -26.20% decrease from the reported $124.8M in 2024. The forecast for 2026 is $34.74M, followed by $61.48M for 2027, $762.32M for 2028, and $1.57B for 2029.

What is Roivant Sciences’s net income forecast?

Roivant Sciences's net income forecast for the fiscal year ending in March 2025 stands at $-605M, representing a -113.91% decrease from the reported $4.35B in 2024. Projections indicate $-804M in 2026, $-911M in 2027, $-388M in 2028, and $163.44M in 2029.